摘要
从1983年Marshall和Warren首次从胃黏膜中分离出幽门螺旋杆菌(Helicobacter pylori,H.pylori)以来,迄今已走过了33个年头,现已确定H.pylori不仅仅与慢性胃病密切相关,且与多个系统疾病相关.随着对H.pylori感染广泛深入的研究,对H.pylori致病性的认识、防治方法上均有显著的提高.2015年邹全明教授团队重组H.pylori口服疫苗的开发,为预防H.pylori感染显示出广阔的前景.2014年日本旨在通过全人群根除H.pylori感染降低胃癌发病的计划,引起广泛的关注.H.pylori感染是一种传染病,我国人群感染率约56%,因此,加强H.pylori细菌学和发病机制的研究,做好其防治,寻求抗菌疗效高、耐药性低的治疗方案、提高感染患者的可及性是一项任重而道远的艰巨任务.
From the first isolation of Helicobacter pylori（H. pylori） from the gastric mucosa by Marshall and Warren in 1983, 33 years have passed. H.pylori has been found to be closely associated not only with chronic gastric diseases but also with multiple system diseases. Advances in research of H. pylori infection has led to a better understanding of the pathogenicity of H. pylori and the prevention and treatment of related disease. In 2015, Professor Zou＇s team developed oral recombinant H. pylori vaccine, which is promising in the prevention of H. pylori infection. Japan aims to reduce the risk of H. pylori infection in the whole population in 2014 to reduce the incidence of gastric cancer, which has caused widespread concern. H. pylori infection is a kind of infectious disease, and the infection rate in China is about 56%.Therefore, it is of great clinical importance to strengthen the research on bacteriology and pathogenesis of H. pylori, improve the prevention and treatment related diseases, and seek antibacterial regimens with better efficacy and lower drug resistance.
出处
《世界华人消化杂志》
CAS
2016年第16期2454-2462,共9页
World Chinese Journal of Digestology
关键词
幽门螺旋杆菌
致病性
治疗方案选择
保护作用
预防
Helicobacter pylori
Pathogenicity
Treatment options
Protective effect
Prevention
